MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2016 International Congress

    Objective movement recording in PD patient before and after STN-DBS

    D. Flisar, B. Pikš, B. Meglic, Z. Pirtošek, G. Kramberger (Ljubljana, Slovenia)

    Objective: Case study: objective recording of motor fluctuations and dyskinesia in PD patient before and after STN-DBS by using continuous accelerometry system and automated computer…
  • 2016 International Congress

    Age associated effects of levodopa administration on striatal acetylcholinesterase activity

    M. Messripour, A. Mesripour (Isfahan, Islamic Republic of Iran)

    Objective: The aim of this study was to compare short- and long-term effects of levodopa on acetylcholinesterase activity in young and old rat brain striatum.…
  • 2016 International Congress

    ADCY5 screening in paediatric-onset hyperkinetic movement disorders: Report of three new Italian families

    M. Carecchio, N.E. Mencacci, G. Zorzi, F. Zibordi, C. Fusco, A. Iodice, L. Veneziano, C. Barzaghi, L. 'RBibo, N. Wood, B. Garavaglia, N. Nardocci (Milan, Italy)

    Objective: To report three new cases with pathogenic ADCY5 mutations and describe their clinical phenotype. Background: ADCY5 is a recently identified gene responsible for a…
  • 2016 International Congress

    Developing a new home monitoring device for dyskinesia in Parkinson’s disease

    J.E. Alty, J. Cosgrove, M.A. Lones, S. Jamieson, P. Duggan-Carter, C. Peacey, C. Wicks, R.F. Naylor, A.J. Turner, S.L. Smith (Leeds, United Kingdom)

    Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…
  • 2016 International Congress

    A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease

    S. Kushwaha, R. Mistry, A. Anthony, S. Khurana (Delhi, India)

    Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…
  • 2016 International Congress

    Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia

    G. Gangarossa, M. Guzman, V. Prado, M. Prado, S. Daumas, S. El Mestikawy, E. Valjent (Paris, France)

    Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…
  • 2016 International Congress

    Objective data in Parkinson’s disease therapy management – A retrospective analysis of the Parkinson’s kinetigraph (PKG) database

    P. Lynch, Y. Zoellner, S. McGregor, M. Home (Minnetonka, MN, USA)

    Objective: To assess whether patients who received a PKG analysis in routine care featured improved PD symptom scores over time using the PKG central repository.…
  • 2016 International Congress

    MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum

    G. Chen, S. Nie, K. Ma, C. Han, Y. Xu, Z. Zhang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

    Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…
  • 2016 International Congress

    AntiParkinsonian effects of the “radiprodil and tozadenant” combination in MPTP-treated marmosets

    A. Michel, J.M. Nicolas, S. Rose, M. Jackson, P. Colman, W. Briône, D. Sciberras, P. Muglia, D. Scheller, M. Citron, P. Downey (Braine L'Alleud, Belgium)

    Objective: Investigate a combination of two clinically tested drugs, the NR2B antagonist Radiprodil and the A2A antagonist Tozadenant in unilaterally 6-OHDA-lesioned rats and in MPTP-treated…
  • 2016 International Congress

    Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in the management of idiopathic Parkinson’s disease: Results of our first 20 cases

    E.M. Rezk, A.A.E. Shakal, S.M. Tourky (Tanta-Gharbeya, Egypt)

    Objective: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is widely accepted as a treatment for advanced Parkinson's disease (PD). However, published studies were…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 44
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley